27303795|t|Novel protein - inhibitor interactions in site 3 of Ca(2+)-bound S100B as discovered by X-ray crystallography
27303795|a|Structure-based drug discovery is under way to identify and develop small-molecule S100B inhibitors (SBiXs). Such inhibitors have therapeutic potential for treating malignant melanoma, since high levels of S100B downregulate wild-type p53 tumor suppressor function in this cancer. Computational and X-ray crystallographic studies of two S100B - SBiX complexes are described, and both compounds (apomorphine hydrochloride and ethidium bromide) occupy an area of the S100B hydrophobic cleft which is termed site 3. These data also reveal novel protein - inhibitor interactions which can be used in future drug-design studies to improve SBiX affinity and specificity. Of particular interest, apomorphine hydrochloride showed S100B -dependent killing in melanoma cell assays, although the efficacy exceeds its affinity for S100B and implicates possible off-target contributions. Because there are no structural data available for compounds occupying site 3 alone, these studies contribute towards the structure-based approach to targeting S100B by including interactions with residues in site 3 of S100B.
27303795	0	5	Novel	T080	C0205314
27303795	6	13	protein	T116,T123	C0033684
27303795	16	25	inhibitor	T120	C0243077
27303795	26	38	interactions	T169	C1704675
27303795	42	70	site 3 of Ca(2+)-bound S100B	T116,T123	C3658228
27303795	74	84	discovered	T052	C1880355
27303795	88	109	X-ray crystallography	T059	C0206755
27303795	110	140	Structure-based drug discovery	T062	C0920472
27303795	178	192	small-molecule	T109	C1328819
27303795	193	198	S100B	T116,T123	C3658228
27303795	199	209	inhibitors	T120	C0243077
27303795	211	216	SBiXs	T120	C0243077
27303795	224	234	inhibitors	T120	C0243077
27303795	240	251	therapeutic	T169	C0302350
27303795	252	261	potential	T080	C3245505
27303795	266	274	treating	T169	C1522326
27303795	275	293	malignant melanoma	T191	C0025202
27303795	316	321	S100B	T116,T123	C3658228
27303795	322	334	downregulate	T044	C0013081
27303795	335	348	wild-type p53	T116,T123	C0080055
27303795	349	374	tumor suppressor function	T043	C1325410
27303795	383	389	cancer	T191	C0025202
27303795	391	404	Computational	T059	C4297010
27303795	409	439	X-ray crystallographic studies	T059	C0206755
27303795	447	452	S100B	T116,T123	C3658228
27303795	455	459	SBiX	T120	C0243077
27303795	460	469	complexes	T104	C1704241
27303795	494	503	compounds	T080	C0205198
27303795	505	530	apomorphine hydrochloride	T109,T121	C0237406
27303795	535	551	ethidium bromide	T109,T121	C0019873
27303795	575	580	S100B	T116,T123	C3658228
27303795	581	592	hydrophobic	T080	C0598629
27303795	593	598	cleft	T082	C0205242
27303795	615	621	site 3	T082	C0205675
27303795	629	633	data	T078	C1511726
27303795	652	659	protein	T116,T123	C0033684
27303795	662	671	inhibitor	T120	C0243077
27303795	672	684	interactions	T169	C1704675
27303795	713	732	drug-design studies	T090	C0013171
27303795	736	743	improve	T033	C0184511
27303795	744	748	SBiX	T120	C0243077
27303795	749	757	affinity	T070	C1510827
27303795	762	773	specificity	T081	C0037791
27303795	799	824	apomorphine hydrochloride	T109,T121	C0237406
27303795	832	837	S100B	T116,T123	C3658228
27303795	849	856	killing	T043	C0599733
27303795	860	873	melanoma cell	T025	C1513095
27303795	874	880	assays	T059	C1510438
27303795	895	903	efficacy	T080	C1280519
27303795	916	924	affinity	T070	C1510827
27303795	929	934	S100B	T116,T123	C3658228
27303795	1006	1021	structural data	T078	C1511726
27303795	1036	1045	compounds	T080	C0205198
27303795	1056	1062	site 3	T082	C0205675
27303795	1076	1083	studies	T062	C2603343
27303795	1145	1150	S100B	T116,T123	C3658228
27303795	1164	1176	interactions	T169	C1704675
27303795	1182	1190	residues	T077	C1709915
27303795	1194	1200	site 3	T082	C0205675
27303795	1204	1209	S100B	T116,T123	C3658228